Tobira Therapeutics to Present at Upcoming Investor and Scientific Conferences in June 2015

SOUTH SAN FRANCISCO, Calif., June 1, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced that the company will present at the following conferences this month:

• Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 11:30 a.m. ET in New York City
• JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 9:30 a.m. ET at the St. Regis New York in New York City
• Paris NASH Symposium on Friday, June 26, 2015 at 12:30 p.m. CET at the Institut Pasteur in Paris

A live audio webcast of the Jefferies and JMP presentations will be accessible on the Investors page of the Company's website at www.tobiratherapeutics.com. Replays of these two presentations will be available at the same location for 90 days following the conference.

About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV. Tobira is actively enrolling patients in a Phase 2b clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis. For additional information on the CENTAUR study, please visit clinicaltrials.gov using the identifier NCT02217475 or www.centaurstudy.com. Learn more about Tobira at www.tobiratherapeutics.com.

Tobira Contacts:
Chris Peetz
Chief Financial Officer
Tobira Therapeutics
(650) 351-5018
[email protected]

Mark Corbae
Canale Communications
(619) 849-5375
[email protected]

SOURCE Tobira Therapeutics

Related Links

http://www.tobiratherapeutics.com